Literature DB >> 9256310

Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance.

M Navarro1, R Cervera, J Font, J C Reverter, J Monteagudo, G Escolar, A López-Soto, A Ordinas, M Ingelmo.   

Abstract

OBJECTIVE: To investigate the prevalence and characteristics of anti-endothelial cell antibodies (AECA) in a large cohort of patients with several well defined systemic autoimmune diseases, in order to determine their relationship with the clinical and laboratory features of these diseases.
METHODS: Clinical and laboratory features of 216 consecutive Caucasian patients were prospectively studied. One hundred and seven patients had been diagnosed as having a primary systemic vasculitis-specifically, 39 had temporal arteritis (TA), 25 polyarteritis nodosa (PAN), 9 Wegener's granulomatosis (WG), and 34 Behcet's disease (BD)-, 90 patients had systemic lupus erythematosus (SLE), and 19 had a primary Sjogren's syndrome (SS). The AECA were determined by ELISA.
RESULTS: One hundred and four (48%) patients with systemic autoimmune diseases were found to have a positive titre of AECA. Specifically, AECA were detected in 41 (38%) patients with a primary systemic vasculitis (13 (33%) with TA, 14 (56%) with PAN, 5 (56%) with WG and 9 (26%) with BD), in 58 (63%) patients with SLE, and in 5 (26%) patients with a primary SS. In patients with a primary systemic vasculitis, those with AECA were found to have an increased prevalence of disease activity (P < 0.05). In SLE patients, those with AECA were found to have an increased prevalence of vascular lesions (P < 0.05), lupus nephropathy (P < 0.05), and anticardiolipin antibodies (aCL) (P < 0.001).
CONCLUSIONS: Patients with systemic autoimmune diseases have a high prevalence of AECA and they are associated with the presence of vascular lesions, nephropathy, and aCL in SLE, as well as with disease activity in several primary systemic vasculitis (TA, PAN, WG and BD).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9256310     DOI: 10.1177/096120339700600608

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

1.  Peroxiredoxin 2 is a novel autoantigen for anti-endothelial cell antibodies in systemic vasculitis.

Authors:  R Karasawa; M S Kurokawa; K Yudoh; K Masuko; S Ozaki; T Kato
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

Review 2.  Antiendothelial cell antibodies in vasculitis and connective tissue disease.

Authors:  C Belizna; A Duijvestijn; M Hamidou; J W Cohen Tervaert
Journal:  Ann Rheum Dis       Date:  2006-03-28       Impact factor: 19.103

Review 3.  Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

Authors:  Salma Siddique; Jessie Risse; Guillaume Canaud; Stéphane Zuily
Journal:  Curr Rheumatol Rep       Date:  2017-09-04       Impact factor: 4.592

4.  Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus.

Authors:  R Wu; E Svenungsson; I Gunnarsson; C Haegerstrand-Gillis; B Andersson; I Lundberg; L S Elinder; J Frostegård
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

5.  Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis.

Authors:  Paola Margutti; Paola Matarrese; Fabrizio Conti; Tania Colasanti; Federica Delunardo; Antonella Capozzi; Tina Garofalo; Elisabetta Profumo; Rachele Riganò; Alessandra Siracusano; Cristiano Alessandri; Bruno Salvati; Guido Valesini; Walter Malorni; Maurizio Sorice; Elena Ortona
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

6.  Association of ferritin antibodies with Takayasu arteritis.

Authors:  K Große; T Witte; F Moosig; B F Hoyer; C Lansche; R E Schmidt; N T Baerlecken
Journal:  Clin Rheumatol       Date:  2014-09-02       Impact factor: 2.980

7.  Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium.

Authors:  Tho Pham; Christopher J Gregg; Felix Karp; Renee Chow; Vered Padler-Karavani; Hongzhi Cao; Xi Chen; Joseph L Witztum; Nissi M Varki; Ajit Varki
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

8.  Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach.

Authors:  Alexis Régent; Hanadi Dib; Kim H Ly; Christian Agard; Mathieu C Tamby; Nicolas Tamas; Babette Weksler; Christian Federici; Cédric Broussard; Loïc Guillevin; Luc Mouthon
Journal:  Arthritis Res Ther       Date:  2011-06-28       Impact factor: 5.156

9.  Identification and characterization of the carboxy-terminal region of Sip-1, a novel autoantigen in Behçet's disease.

Authors:  Federica Delunardo; Fabrizio Conti; Paola Margutti; Cristiano Alessandri; Roberta Priori; Alessandra Siracusano; Rachele Riganò; Elisabetta Profumo; Guido Valesini; Maurizio Sorice; Elena Ortona
Journal:  Arthritis Res Ther       Date:  2006-04-12       Impact factor: 5.156

Review 10.  Vasculitis Pathogenesis: Can We Talk About Precision Medicine?

Authors:  Seza Ozen; Ezgi Deniz Batu
Journal:  Front Immunol       Date:  2018-08-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.